Tag Archives: IBS

SeeThruEquity RSHO Raúl Elizalde

Medical Marijuana, Inc. Investment Axim Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome (IBS) with CanChew Plus Cannabidiol (CBD) Chewing Gum

Medical Marijuana, Inc. Investment Axim Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome (IBS) with CanChew Plus Cannabidiol (CBD) Chewing Gum

NEW YORK, March 7, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.

Axim Biotech - MedChew Rx

AXIM Biotech Enters IBS Clinical Trial for Canchew CBD Chewing Gum

NEW YORK, Jan. 18, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus® cannabidiol (CBD) gum at Wageningen University in the Netherlands.

Qualifying Conditions

Illinois to Consider Adding Conditions to Medical Cannabis Program

On Monday, May 2, 2016, the Illinois Medical Cannabis Advisory Board will meet to discuss the possibility of approving additional conditions for the state’s list of conditions that can qualify a patient to use medical cannabis.


Top